fda peptide regulations bpc-157 igf-1 cerebrolysin panel votes to ease restrictions on The FDA is reviewing which

As a research tool for investigating fundamental questions about tissue homeostasis, aging mechanisms, and regenerative capacity, the GLOW Blend provides investigators with unprecedented ability to study the integrated biological networks underlying tissue repair while maintaining the experimental control afforded by well-characterized individual components

Our clinics are located in Southampton, PA and Langhorne, PA

Emerging research suggests BPC-157's benefits extend beyond direct tissue repair

FDA inspections have repeatedly found research-grade peptides with inaccurate dosing and contamination, which is actually why the FDA moved several peptides to Category 2 back in 2023